Irina Staatz-Granzer
Chairman chez INNATE PHARMA
Fortune : 59 231 $ au 31/03/2024
Profil
Dr. Irina Staatz-Granzer is an Independent Director at Aelis Farma SA, a Co-Chairman Supervisory Board at Emergence Therapeutics AG, a Chairman at Talix Therapeutics NV, a Chairman-Supervisory Board at Innate Pharma SA, a Chairman at Pharma-Lizenz-Club Deutschland and a Vice Chairman & Chief Executive Officer at Staatz Business Development & Strategy.
She is on the Board of Directors at Aelis Farma SA and Staatz Business Development & Strategy.
Dr. Staatz-Granzer was previously employed as a Chairman & Chief Executive Officer by BliNK Biomedical SAS, a Chairman by BliNK Therapeutics Ltd., a Chief Business Officer by FIBREX Medical, Inc., a Chief Executive Officer by U3 Pharma AG, a Chief Executive Officer by BioNet Pharma GmbH, and a Principal by HERMAL Kurt Herrmann GmbH & Co. oHG.
She received her undergraduate degree from Philipps University of Marburg and a doctorate degree from Eberhard Karls Universität Tübingen.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
INNATE PHARMA SA CLASS A
0,03% | 31/12/2022 | 25 100 ( 0,03% ) | 59 231 $ | 31/03/2024 |
Postes actifs de Irina Staatz-Granzer
| Sociétés | Poste | Début |
|---|---|---|
| INNATE PHARMA | Chairman | 01/01/2024 |
| AELIS FARMA | Director/Board Member | 01/01/2022 |
| Staatz Business Development & Strategy | Founder | 19/07/2010 |
| Pharma-Lizenz-Club Deutschland | Chairman | - |
| Talix Therapeutics NV | Chairman | 01/01/2017 |
Emergence Therapeutics AG
 Emergence Therapeutics AG Pharmaceuticals: MajorHealth Technology Emergence Therapeutics AG is biopharmaceutical company. It develops novel antibody drug conjugate. The company was founded by Jack Elands and Xavier Preville and is headquartered in Duisburg, Germany. | Chairman | 01/01/2019 |
Anciens postes connus de Irina Staatz-Granzer
| Sociétés | Poste | Fin |
|---|---|---|
FIBREX Medical, Inc.
 FIBREX Medical, Inc. Miscellaneous Commercial ServicesCommercial Services FIBREX Medical Inc. is a development stage bio-pharmaceutical company. Its operational affiliate FIBREX Medical Research & Development GmbH was established in Vienna in February 2001. The company was founded to convert high impact scientific discovery into pharmaceutical products for important diseases. The company aims to become a leader in the development and commercialization of pharmaceuticals targeting fundamental mechanisms of inflammation and tissue injury. While inflammation is highly desirable to defend the organism against foreign particles and infections, it can become harmful and destructive if it runs unchecked. Inflammation-based tissue injury is well known as a major component in the pathogenesis and progression of important diseases such as myocardial infarction, septic and hemorrhagic shock, graft rejection, or rheumatoid arthritis. In addition, endothelial dysfunction in inflamed tissues leads to capillary leak and deleterious edema formation, aggravating organ dysfunction. | Corporate Officer/Principal | 05/02/2013 |
BliNK Biomedical SAS
 BliNK Biomedical SAS BiotechnologyHealth Technology BliNK Biomedical SAS is a French company that specializes in cutting-edge technology for identifying rare antibody-secreting cells from humans and other species. The company is based in Marseille, France. The company's technology is based on validated platforms, isaac and vivascreen, which provide a highly efficient and deep mining process. The CEO of the company is Jack Elands. | Chief Executive Officer | - |
BliNK Therapeutics Ltd.
 BliNK Therapeutics Ltd. BiotechnologyHealth Technology BliNK Therapeutics Ltd. is a holding company which produces monoclonal antibodies using a novel platform. The platform technology provides a new way of activating the immune system’s B cells to produce antibodies in response to a specific antigen. The company was founded in 2011 and is headquartered in Marlow, the United Kingdom. | Chairman | - |
| ░░░░░░ ░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | - |
| ░░░░░░ ░░░░ ░░░░░░░░ ░░░░ ░░░░░ ░░░ ░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
Formation de Irina Staatz-Granzer
| Eberhard Karls Universität Tübingen | Doctorate Degree |
| Philipps University of Marburg | Undergraduate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| INNATE PHARMA | Health Technology |
| AELIS FARMA | Health Technology |
| Entreprise privées | 10 |
|---|---|
FIBREX Medical, Inc.
FIBREX Medical, Inc. Miscellaneous Commercial ServicesCommercial Services FIBREX Medical Inc. is a development stage bio-pharmaceutical company. Its operational affiliate FIBREX Medical Research & Development GmbH was established in Vienna in February 2001. The company was founded to convert high impact scientific discovery into pharmaceutical products for important diseases. The company aims to become a leader in the development and commercialization of pharmaceuticals targeting fundamental mechanisms of inflammation and tissue injury. While inflammation is highly desirable to defend the organism against foreign particles and infections, it can become harmful and destructive if it runs unchecked. Inflammation-based tissue injury is well known as a major component in the pathogenesis and progression of important diseases such as myocardial infarction, septic and hemorrhagic shock, graft rejection, or rheumatoid arthritis. In addition, endothelial dysfunction in inflamed tissues leads to capillary leak and deleterious edema formation, aggravating organ dysfunction. | Commercial Services |
HERMAL Kurt Herrmann GmbH & Co. oHG
 HERMAL Kurt Herrmann GmbH & Co. oHG Pharmaceuticals: MajorHealth Technology HERMAL Kurt Herrmann GmbH & Co. oHG provides skin care products. The company develops products for the treatment of skin related diseases. It is a dermatological company with marketing and sales departments throughout Europe and a production unit based in Germany. HERMAL Kurt Herrmann was founded in 1946 and is headquartered in Reinbek, Germany. | Health Technology |
U3 Pharma AG
 U3 Pharma AG Miscellaneous Commercial ServicesCommercial Services U3 Pharma AG researches and develops novel targeted therapeutics aimed at treating human disease. It develops products for hyperproliferative diseases such as cancer and commercializes human monoclonal antibody therapies directed against validated proprietary drug targets selected from its portfolio. In addition, it has created a second generation functional genomics platform, TASC, which mimics the progression of a tumor cell as it progresses towards its fully malignant cancerous state. Founded in 2001, the company is headquartered in Martinsried, Germany. | Commercial Services |
BioNet Pharma GmbH
 BioNet Pharma GmbH Miscellaneous Commercial ServicesCommercial Services BioNet Pharma GmbH engages in development of medical devices, pharmaceutical drugs and regenerative medical products. Its pipeline covers pre-clinical and clinical development programs in osteoarthritis, inflammatory joint disease, cartilage injury, and severe gingival inflammation. The company is headquartered in Martinsried, Germany. | Commercial Services |
| Staatz Business Development & Strategy | |
| Pharma-Lizenz-Club Deutschland | |
BliNK Therapeutics Ltd.
BliNK Therapeutics Ltd. BiotechnologyHealth Technology BliNK Therapeutics Ltd. is a holding company which produces monoclonal antibodies using a novel platform. The platform technology provides a new way of activating the immune system’s B cells to produce antibodies in response to a specific antigen. The company was founded in 2011 and is headquartered in Marlow, the United Kingdom. | Health Technology |
BliNK Biomedical SAS
BliNK Biomedical SAS BiotechnologyHealth Technology BliNK Biomedical SAS is a French company that specializes in cutting-edge technology for identifying rare antibody-secreting cells from humans and other species. The company is based in Marseille, France. The company's technology is based on validated platforms, isaac and vivascreen, which provide a highly efficient and deep mining process. The CEO of the company is Jack Elands. | Health Technology |
| Talix Therapeutics NV | |
Emergence Therapeutics AG
Emergence Therapeutics AG Pharmaceuticals: MajorHealth Technology Emergence Therapeutics AG is biopharmaceutical company. It develops novel antibody drug conjugate. The company was founded by Jack Elands and Xavier Preville and is headquartered in Duisburg, Germany. | Health Technology |
